Dose-dependent esomeprasole antisecretory effect: results of long-term intragastric pH monitoring

Aim of investigation. To study antisecretory activity of the first dose of esomeprazole (20 or 40 mg) (Emanera®, «KRKA», Slovenia) by long-term intragastric pH monitoring. Material and methods. Long-term intragastric pH monitoring was carried out in 20 patients with acidrelated diseases by «Gastroskan-24» device («IstokSistema», Fryazino, Russia). In the first 24 hours patients received no antisecretory agents, in the morning of the next day - they received esomeprazole 20 or 40 mg orally 30 min. prior to the breakfast. Median pH, both time with various pH values and area under pH distribution curve, percent of this time with values from 1,0 to 10,0 per day before and after esomeprazole administration were estimated. The respective scores were compared, using Wilcoxon criterion. Differences were considered to be significant at р<0,05. Results. At intake of esomeprazole in a dose of 20 mg higher antisecretory effect in comparison to several earlier investigated omeprazole generics by all studied parameters was found. Intake of 40 mg of esomeprazole was followed by more significant and long-lasting acid suppression, i. e. the dose-dependent antisecretory response was received. The dispersion of individual values was minimal. Conclusions. Esomeprazole generic drug Emanera® in a dose of 40 mg complies requirements to the degree of secretion suppression and predictability required for eradication treatment, treatment of severe gastroesophageal reflux disease (GERD), GERD with extraesophageal manifestations, Barret's esophagus and gastro-intestinal bleeding (after iv treatment stage) and can be considered as a drug of choice in these states. According to its antisecretory activity Emanera 20 mg has advantages over omeprazole generics that allows to recommend it for application at functional dyspepsia, non-erosive reflux disease, mild GERD, for GERD maintenance therapy, and also for the treatment and prophylaxis of NSAID-associated gastropathies.

кислотозависимые заболевания, длительный мониторинг интрагастрального рН, эзомепразол, Эманера®

1. Маев И.В. Современные подходы к лечению язвенной болезни желудка и двенадцатиперстной кишки. Лечащий врач 2003; 5:4-8.

2. Моyyaedi P., Talley N. Gastroesophageal reflux disease. Lancet 2006; 367:2086-100.

3. Rodrigues A.D., Rushmore T.H. Cytochrome P450 pharmacogenetics in drug development: In vitro studies and clinical consequences. Curr Drug Metab 2002; 3:289309.

4. Исаков В.А., Ганская Ж.Ю. Mетаанализ эффективности использования моноизомера и ИПП-рацематов в схемах антихеликобактерной терапии. Клин гастроэнтерол гепатол. Русское издание 2008; 6:463-8.

5. Решетников О.В., Курилович С.А., Шлыкова Л.Г. Почему необходимо суточное мониторирование рН? Консилиум 1999; 4(7):37-40.

6. Трифонов М.М. Внутрижелудочная рН-метрия: клинические методики и приборы. Здравоохранение и медтехника 2003; 4:40-1.

7. Курилович С.А., Решетников О.В., Шлыкова Л.Г. и др. Суточное мониторирование рН: место в практической и научной гастроэнтерологии //Сиб. журн гастроэнтерол гепатол 1998; 1(7):313-4.

8. Andersson T., Rohss K., Hassan-Alin M. Pharmacokinetics (PK) and dose-response relationship of Esomeprazole Gastroenterology 2000; 118(4)Suppl:1210.

9. Andersson T., Bredberg E., Hassan-Alin M. Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole. Aliment Pharmacol Ther 2001; 15(10):1563-9.

10. Lind T., Rydberg L., Kyleback A. et al. Esomeprazole improved acid control vs omeprazole in patient with symptoms of gastrooesophageal reflux disease Aliment Pharmacol Ther 2000; 14(7):861-7.

11. Sugimoto М. et al. Evidence that the degree and duration of acid suppression are related to H. pylori eradication by triple therapy. Helicobacter 2007; 12(4):317-23.

12. Röhss K., Lind T., Wilder-Smith C. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with GOR symptoms. Eur J Clin Pharmacol 2004; 60(8):531-9.

13. Bioequivalence study report summary of randomized, open-label, 2-way crossover bioequivalence study of two esomeprazole 40 mg gastro-resistant dosage forms in healthy volunteers. Data on file, KRKA, d.d., 2015.

14. Курилович C.А., Чекалина Е.А, Белковец А.В., Щербакова Л.В. Антисекреторная активность эзомепразола (Эманеры) у пациентов с кислотозависимыми заболеваниями. Врач 2015; 8:35-40.

15. Shi S., Klotz U. Proton pomp inhibitors an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol 2008; 64:935-51.

16. Shin J.M., Sachs G. Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep 2008; 10:528-34.